---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269479"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:45:10.373390+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# Intellia reports patient death in nex-z trial; awaits FDA clinical hold; lonvo-z on track

## Summary
- Patient who had Grade 4 liver transaminase elevations after nex-z dose in MAGNITUDE Phase 3 trial died; FDA clinical hold letter pending.
- Phase 3 HAELO trial of lonvo-z for hereditary angioedema completed enrollment; topline data expected mid-2026.
- Cash, equivalents and marketable securities ~$670M as of Sept 30, 2025; company expects to fund ops into mid-2027.
- Longer-term Phase 1 clinical data for nex-z in ATTR-CM to be presented Nov 10 at AHA 2025.

## SEC filing metadata
- accession: 0001193125-25-269479
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525269479/0001193125-25-269479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525269479/d53244d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269479
- JSON: https://secwatch.observer/filing/0001193125-25-269479.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269479.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.